针刺治疗血管性认知障碍的疗效及改善外周Treg细胞稳态的研究

注册号:

Registration number:

ITMCTR2025001271

最近更新日期:

Date of Last Refreshed on:

2025-06-26

注册时间:

Date of Registration:

2025-06-26

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

针刺治疗血管性认知障碍的疗效及改善外周Treg细胞稳态的研究

Public title:

Study on the Therapeutic Effect of Acupuncture on Vascular Cognitive Impairment and the Improvement of Peripheral Treg Cell Homeostasis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺治疗血管性认知障碍的疗效及改善外周Treg细胞稳态的研究

Scientific title:

Study on the Therapeutic Effect of Acupuncture on Vascular Cognitive Impairment and the Improvement of Peripheral Treg Cell Homeostasis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

祁赛

研究负责人:

张雪竹

Applicant:

QiSai

Study leader:

ZhangXuezhu

申请注册联系人电话:

Applicant telephone:

15822217610

研究负责人电话:

Study leader's telephone:

13652024902

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15822217610@139.com

研究负责人电子邮件:

Study leader's E-mail:

zhangxuezhu1999@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

天津市西青区昌凌路88号

研究负责人通讯地址:

天津市西青区昌凌路88号

Applicant address:

88 Changling Road Xiqing District Tianjin

Study leader's address:

88 Changling Road Xiqing District Tianjin

申请注册联系人邮政编码:

Applicant postcode:

300381

研究负责人邮政编码:

Study leader's postcode:

300381

申请人所在单位:

天津中医药大学第一附属医院

Applicant's institution:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

TYLL2024[K]字039

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

天津中医药大学第一附属医院医学伦理委员会

Name of the ethic committee:

IRB of The First Teaching Hospital of Tianjin University of TCM

伦理委员会批准日期:

Date of approved by ethic committee:

2024/8/22 0:00:00

伦理委员会联系人:

郑子琦

Contact Name of the ethic committee:

Zheng Ziqi

伦理委员会联系地址:

天津市西青区昌凌路88号

Contact Address of the ethic committee:

88 Changling Road Xiqing District Tianjin

伦理委员会联系人电话:

Contact phone of the ethic committee:

022-27986258

伦理委员会联系人邮箱:

Contact email of the ethic committee:

yfyiec@163.com

研究实施负责(组长)单位:

天津中医药大学第一附属医院

Primary sponsor:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

天津市西青区昌凌路88号

Primary sponsor's address:

88 Changling Road Xiqing District Tianjin

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津市

市(区县):

西青区

Country:

China

Province:

TianJin

City:

Xiqing District

单位(医院):

天津中医药大学第一附属医院

具体地址:

天津市西青区昌凌路88号

Institution
hospital:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Address:

88 Changling Road Xiqing District Tianjin

国家:

中国

省(直辖市):

天津市

市(区县):

西青区

Country:

China

Province:

Tianjin

City:

Xiqing District

单位(医院):

天津中医药大学第一附属医院

具体地址:

天津市西青区昌凌路88号

Institution
hospital:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Address:

88 Changling Road Xiqing District Tianjin

经费或物资来源:

国家自然科学基金资助

Source(s) of funding:

Supported by the National Natural Science Foundation of China

研究疾病:

血管性痴呆

研究疾病代码:

Target disease:

Vascular Dementia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

揭示三焦针法对VD患者认知功能的治疗效果。阐明Treg数量和功能损伤——外周炎症反应——脑神经炎症——认知损伤——针刺效应之间的关系。

Objectives of Study:

Explore the therapeutic effect of San Jiao acupuncture on cognitive function of VD patients. To elucidate the relationship between the number of Treg and functional impairment -- peripheral inflammatory response -- cerebral neuroinflammation -- cognitive impairment -- acupuncture effect.

药物成份或治疗方案详述:

本研究以VD患者为研究对象,将患者随机分为西药对照组和针刺治疗组,分别给予相应治疗,持续12周。采用临床常用量表,从记忆、定向、语言、逻辑思维、视空间结构能力等方面评价针刺治疗前后VD患者认知能力、日常生活能力的变化,明确针刺治疗VD的临床疗效。 治疗结束后,取正常对照组及VD患者外周血,分离其中的单个核细胞。采用荧光抗体标记细胞,并用流式细胞术进行检测。通过观察针刺对Treg数量;Treg增殖(ki67+Treg);Treg功能相关指标—Treg表面共刺激分子(CTLA-4+Treg、CD28+Treg)及配体CD80/CD86(CD11c、MHC-II、CD80、CD86)表达;效应T细胞亚群的数量、比例、增殖(ki67+CD3、ki67+CD4、ki67+CD8)和凋亡(Annexin V/7-AAD)等,明确针刺是否通过调控CTLA-4/CD28协同刺激途径维持外周Treg细胞的稳态及功能。 通过观察针刺前后VD患者外周血内细胞因子水平的变化,阐明针刺对Treg功能及VD外周炎症反应的调控作用。

Description for medicine or protocol of treatment in detail:

In this study VD patients were randomly divided into western medicine control group and acupuncture treatment group respectively and were given corresponding treatment for 12 weeks. The changes of cognitive ability and daily living ability of VD patients before and after acupuncture treatment were evaluated by using the commonly used clinical scales from the aspects of memory orientation language logical thinking visual-spatial structure ability etc. and the clinical effect of acupuncture on VD patients was confirmed. After treatment peripheral blood of normal control group and VD patients were collected and mononuclear cells were isolated. The cells were labeled with fluorescent antibodies and detected by flow cytometry. The number of Treg induced by acupuncture was observed. Treg proliferation (ki67+Treg); Treg functional indicators - Treg surface co-stimulatory molecules (CTLA-4+Treg CD28+Treg) and ligand CD80/CD86 (CD11c MHC-II CD80 CD86) expression; The number proportion proliferation (ki67+CD3 ki67+CD4 ki67+CD8) and apoptosis (Annexin V/7-AAD) of effector T cell subsets were determined to determine whether acupuncture maintained the homeostasis and function of peripheral Treg cells by regulating the CTLA-4/CD28 co-stimulation pathway. By observing the changes of cytokine levels in peripheral blood of VD patients before and after acupuncture the regulation effect of acupuncture on Treg function and peripheral inflammation of VD was elucidated.

纳入标准:

研究对象选择: 选取50-85岁的正常老年人30例、VD患者80例。 设立正常对照组的目的:是取其数据作为基线,以了解VD患者免疫炎症损伤的特点及针刺的调控作用。 A. 正常老年人纳入标准 年龄50-85岁之间,男女不限,受教育程度初中及以上;可以存在高血压病史、冠心病病史、糖尿病病史等既往病史,但须稳定控制。 B. VD患者诊断标准 西医诊断标准 根据2019年中国医师协会神经内科分会认知障碍专业委员会《2019年中国血管性认知障碍诊治指南》和2014年国际血管行为和认知障碍学会《2014 VASCOG共识:血管性认知障碍的诊断标准》的诊断标准,并根据临床痴呆分级表(CDR)标准确定轻中度痴呆。 中医诊断标准 中医学文献中无VD疾病名称,但根据其发病特点及临床表现,将其归属于中医学“健忘”、“呆病”、“痴呆”等范畴。本研究参照2002年国家卫生部颁布的《中药新药临床研究指导原则》中的“中药新药治疗老年期痴呆的临床指导原则”、田金洲编写的《血管性痴呆的诊断、辨证及疗效判定标准》及《新世纪(第二版)全国高等中医药院校规划教材·中医内科学》拟定的血管性痴呆中医辨证量表 (The scale for the differentiation of syndromes of vascular dementia , SDSVD)进行血管性痴呆中医辨证。它们是肾精亏虚证、痰浊阻窍证、瘀血阻络证 、肝阳上亢证、火热内盛证 、腑滞浊留证、气血亏虚证。各证候满分为30分, ≥7分为该证候诊断成立;≥7~14分为轻度, ≥15~22分为中度 , ≥23~30分为重度。 C. VD患者纳入标准 (1)符合上述血管性痴呆诊断标准; (2)符合多发梗塞性痴呆或皮质下动脉硬化性脑病诊断标准; (3)符合临床痴呆评定表(CDR)中轻度和中度标准; (4)简易精神状态检查(MMSE)评分≦24分(中学以上);≦20分(小学程度),≦17分(文盲); (5)Hachinski缺血量表(HIS)评分≧7分; (6)汉密尔顿抑郁量表≦17分; (7)年龄50-85岁,男女不限,女性应是无生育能力的绝经期后妇女(至少绝经1年以上); (8)受试者自愿参加临床试验,并签署知情同意书; (9)对本研究的意义有正确认识,有良好的依从性; (10)有一定文化程度,既往能阅读简单的报纸文章,意识清醒,无语言障碍,能配合完成相关量表检查。

Inclusion criteria

Research object selection: Thirty normal elderly patients aged 50-85 years and 80 patients with VD were selected. The purpose of setting up the normal control group is to take its data as the baseline to understand the characteristics of immunoinflammatory injury in patients with VD and the regulation effect of acupuncture. A. Inclusion criteria for normal elderly Age 50-85 years old male or female with a junior high school education or above; There may be a history of hypertension coronary heart disease diabetes and other past medical history but must be stable control. B. Diagnostic criteria for VD patients Diagnostic criteria of western medicine According to the 2019 Chinese Guidelines for the Diagnosis and Treatment of Vascular Cognitive Disorders issued by the Cognitive Disorders Professional Committee of the Neurology Branch of the Chinese Medical Doctor Association and the 2014 VASCOG Consensus issued by the International Society for Vascular Behavior and Cognitive Disorders: Diagnostic criteria for Vascular Cognitive Impairment and mild to moderate dementia was determined according to Clinical Dementia Scale (CDR) criteria. TCM diagnostic criteria There is no name of VD disease in Chinese medicine literature but according to its pathogenesis and clinical manifestations it belongs to the categories of "forgetfulness" "stupidness" and "dementia" in Chinese medicine. This study referred to the "Clinical Guiding Principles for the Treatment of senile Dementia with New Chinese Medicines" in the "Guiding Principles for Clinical Research of New Chinese Medicines" issued by the Ministry of Health in 2002 the "Criteria for Diagnosis differentiation and efficacy Evaluation of vascular Dementia" compiled by Tian Jinzhou and the "Planning textbooks for National Colleges of Traditional Chinese Medicine · Internal Medicine of Chinese Medicine in the New Century (second edition)" The scale for the differentiation of syndromes of vascular dementia (SDSVD) was used for TCM differentiation of vascular dementia. They are kidney essence deficiency syndrome phlegm turbidness blocking the body syndrome blood stasis blocking collaterals syndrome liver-yang hyperactivity syndrome fiery internal excessive syndrome fu-organ stagnation syndrome Qi and blood deficiency syndrome. The full score of each syndrome is 30 points ≥7 points is the diagnosis of the syndrome is established; ≥7 to 14 is classified as mild ≥15 to 22 as moderate ≥23 to 30 as severe. C. VD patient inclusion criteria (1) Meet the above diagnostic criteria for vascular dementia; (2) meet the diagnostic criteria for multiple infarct dementia or subcortical arteriosclerotic encephalopathy; (3) Meet the moderate mild and moderate criteria of the Clinical Dementia Rating Scale (CDR); (4) Summary Mental Status Examination (MMSE) score ≦24 points (secondary school or above); ≦20 marks (primary level) ≦17 marks (illiterate); (5) Hachinski Ischemia Scale (HIS) score ≧7 points; (6) Hamilton Depression Scale ≤ 17 points; (7) Age 50-85 years old male or female female should be sterile postmenopausal women (at least 1 year menopause); (8) Subjects voluntarily participate in clinical trials and sign informed consent; (9) Have a correct understanding of the significance of this study and have good compliance; (10) Have a certain degree of education can read simple newspaper articles in the past conscious no language barriers can cooperate with the completion of relevant scales.

排除标准:

VD患者排除标准 (1)阿尔茨海默病或其他原因的痴呆,不符合血管性痴呆的诊断标准; (2)抑郁症或其他精神障碍; (3)因头部损伤患有认知障碍者; (4)有癫痫病史、脑炎病史或能引起痴呆的其他疾病,如帕金森病、亨廷顿病、皮克病等; (5)患有某些能干扰认知功能评价疾病,其中包括嗜酒的病人,或者在过去5年内经DSM-IV标准诊断为吸毒或其他精神性药物滥用者; (6)伴有严重的神经功能缺损者,如便利手偏瘫、各种失语、视听障碍等; (7)患有严重的心、肺、肝、肾脏、造血系统、内分泌系统疾病的患者; (8)在过去30天内曾用过同类治疗的患者。 正常老年人排除标准: 存在脑血管病史及认知障碍病史;存在其他神经系统疾患;存在严重的全身系统疾病,如严重感染、免疫系统疾病、恶性肿瘤、严重肝肾功能不全、血液病等,或存在高血压、糖尿病、冠心病等内科病史且未得到稳定控制的;存在焦虑、抑郁等精神障碍;近期病毒与细菌感染;接触化学毒物史;近期使用过对免疫系统有影响的药物。

Exclusion criteria:

Exclusion criteria for VD patients (1) Alzheimer's disease or other causes of dementia does not meet the diagnostic criteria for vascular dementia; (2) Depression or other mental disorders; (3) Cognitive impairment due to head injury; (4) Have a history of epilepsy encephalitis or other diseases that can cause dementia such as Parkinson's disease Huntington's disease Pick's disease etc.; (5) have certain disorders that can interfere with the assessment of cognitive function including alcohol use or have been diagnosed as a drug or other psychoactive substance abuser by the DSM-IV criteria within the past 5 years; (6) Patients with severe neurological impairment such as convenient hand hemiplegia various aphasia audio-visual impairment etc.; (7) Patients with serious heart lung liver kidney hematopoietic system endocrine system diseases; (8) Patients who have received similar treatment in the past 30 days. Exclusion criteria for normal elderly people There is a history of cerebrovascular disease and cognitive impairment; there are other neurological disorders; there are severe systemic diseases such as severe infection immune system diseases malignant tumors severe liver and kidney dysfunction blood diseases etc. or there is a history of internal diseases such as hypertension diabetes coronary heart disease etc. and they have not been stably controlled; there are mental disorders such as anxiety and depression; recent viral and bacterial infections; history of exposure to chemical toxins; recent use of drugs that affect the immune system.

研究实施时间:

Study execute time:

From 2024-08-22

To      2025-08-22

征募观察对象时间:

Recruiting time:

From 2024-08-22

To      2025-08-22

干预措施:

Interventions:

组别:

针刺治疗组

样本量:

40

Group:

Acupuncture treatment group

Sample size:

干预措施:

针刺

干预措施代码:

Intervention:

Acupuncture

Intervention code:

组别:

西药对照组

样本量:

40

Group:

Western medicine control group

Sample size:

干预措施:

西药

干预措施代码:

Intervention:

Western medicine

Intervention code:

组别:

正常对照组

样本量:

30

Group:

Normal control group

Sample size:

干预措施:

无任何干预

干预措施代码:

Intervention:

Without any intervention

Intervention code:

样本总量 Total sample size : 110

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津市

市(区县):

西青区

Country:

China

Province:

Tianjin

City:

Xiqing District

单位(医院):

天津中医药大学第一附属医院

单位级别:

三级甲等

Institution/hospital:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Level of the institution:

Three-level

测量指标:

Outcomes:

指标中文名:

外周Treg稳态及功能

指标类型:

主要指标

Outcome:

Peripheral Treg homeostasis and function

Type:

Primary indicator

测量时间点:

测量方法:

流式细胞术

Measure time point of outcome:

Measure method:

Flow cytometry

指标中文名:

外周细胞因子水平

指标类型:

主要指标

Outcome:

Peripheral cytokine levels

Type:

Primary indicator

测量时间点:

测量方法:

ELISA法

Measure time point of outcome:

Measure method:

ELISA method

指标中文名:

认知能力

指标类型:

主要指标

Outcome:

cognitive ability

Type:

Primary indicator

测量时间点:

测量方法:

简易精神状态检查表(MMSE)、阿尔茨海默病评估量表-认知分量表(ADAS-cog)、日常生活活动量表(ADL)、临床医生面试和照料者补充的总体变化印象量表(CIBIC-plus)

Measure time point of outcome:

Measure method:

Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive Component (ADAS Cog), Activities of Daily Living (ADL), Clinical Interview and Caregiver Supplemental Overall Impression of Changes Scale (CIBIC plus)

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

外周血

组织:

取自人体静脉血

Sample Name:

peripheral blood

Tissue:

Derived from human venous blood

人体标本去向

使用后销毁

说明

保存期1天

Fate of sample 

Destruction after use

Note:

The shelf life is 1 day

标本中文名:

血清

组织:

取自人静脉血血清

Sample Name:

serum

Tissue:

Obtained from human venous blood serum

人体标本去向

使用后销毁

说明

保存期半年

Fate of sample 

Destruction after use

Note:

Shelf life: half a year

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 50
Min age years
最大 85
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究组成员采用SPSS软件中的“随机数生成器”功能,生成0到1之间的随机数,然后通过“可视分箱”功能将研究患者对象随机分为两组‌,即针刺治疗组和西药对照组。正常对照组按正常老年人纳入标准招募。

Randomization Procedure (please state who generates the random number sequence and by what method):

The research team members used the "random number generator" function in SPSS software to generate random numbers between 0 and 1 and then randomly divided the study patients into two groups using the "visual binning" function namely the acupuncture treatment group and the western medicine control group. The normal control group was recruited according to the inclusion criteria for normal elderly individuals.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验结束后以论文的形式在期刊发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Data will be published as research paper at the end of this trial

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF表和电子资料由本课题组研究人员进行采集、管理和保存。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The CRF form and electronic data are collected managed and stored by the researchers of our research group.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统